
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is viewed positively because a broadening recovery in bioprocessing, life sciences, and diagnostics is underpinning outsized sales growth, with bioprocessing representing more than 25% of revenue and showing strong consumables demand plus >30% growth in equipment orders. Q2 showed resilient execution: revenue was $6.27B, core revenue rose 3.0%, adjusted operating margin was 27.1%, adjusted EPS was $1.94, and free cash flow reached $1.3B in the quarter, while management raised full-year 2026 EPS guidance to $8.45–$8.60. The company’s best-in-class portfolio, high share in chromatography resins, improving end markets, and durable long-term demand from pharma reshoring and expanding molecular diagnostics support confidence that growth can re-accelerate as temporary timing issues normalize.
Bears say
Danaher is viewed negatively because its growth rebound has stalled across key end markets, with bioprocess equipment demand still awaiting a reshoring-driven pickup, Life Sciences instrument demand continuing to decline, and China diagnostics remaining a drag even as sales there are now below $1B annually. The company’s late 2023 divestiture of Veralto left it more concentrated in life sciences and diagnostics, making execution on product demand and acquisition integration more critical just as several recent Life Sciences deals have failed to meet expectations. With the stock now vulnerable to a 15x P/E, investors appear less willing to award the company a premium, especially if frustration persists over sluggish organic growth and limited evidence that press releases will translate into purchase orders.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares